Machina Capital S.A.S. Makes New $1.65 Million Investment in Gilead Sciences, Inc. $GILD

Machina Capital S.A.S. acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 14,848 shares of the biopharmaceutical company’s stock, valued at approximately $1,648,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in GILD. Brighton Jones LLC boosted its holdings in Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after buying an additional 2,450 shares in the last quarter. Bison Wealth LLC bought a new position in shares of Gilead Sciences in the fourth quarter valued at $215,000. Sivia Capital Partners LLC lifted its position in shares of Gilead Sciences by 16.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after acquiring an additional 602 shares during the last quarter. Valeo Financial Advisors LLC boosted its stake in shares of Gilead Sciences by 26.7% during the 2nd quarter. Valeo Financial Advisors LLC now owns 13,262 shares of the biopharmaceutical company’s stock worth $1,470,000 after acquiring an additional 2,795 shares in the last quarter. Finally, BankPlus Trust Department grew its holdings in shares of Gilead Sciences by 333.3% in the 2nd quarter. BankPlus Trust Department now owns 650 shares of the biopharmaceutical company’s stock worth $72,000 after acquiring an additional 500 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Scotiabank initiated coverage on shares of Gilead Sciences in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $140.00 target price for the company. UBS Group lifted their target price on Gilead Sciences from $145.00 to $155.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Citigroup upped their price objective on shares of Gilead Sciences from $140.00 to $156.00 and gave the company a “buy” rating in a research note on Tuesday, January 27th. Wells Fargo & Company lifted their target price on shares of Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, December 10th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $136.73.

Insider Buying and Selling

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 115,640 shares of Gilead Sciences stock in a transaction that occurred on Friday, January 23rd. The stock was sold at an average price of $135.00, for a total value of $15,611,400.00. Following the transaction, the chief executive officer directly owned 566,698 shares of the company’s stock, valued at $76,504,230. The trade was a 16.95% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $125.08, for a total value of $625,400.00. Following the transaction, the director owned 8,920 shares of the company’s stock, valued at approximately $1,115,713.60. This trade represents a 35.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 257,397 shares of company stock valued at $33,385,512. 0.27% of the stock is owned by corporate insiders.

Gilead Sciences Stock Performance

GILD opened at $146.23 on Thursday. The stock has a 50-day moving average of $126.41 and a 200-day moving average of $120.40. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. Gilead Sciences, Inc. has a 52-week low of $93.37 and a 52-week high of $146.73. The company has a market cap of $181.42 billion, a PE ratio of 22.67, a price-to-earnings-growth ratio of 0.76 and a beta of 0.36.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.